Activity of BAL 4815 against filamentous fungi

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1083-1086

  de la Escalera, C Martín ^a   Aller, A I ^a   Lopez Oviedo E ^a   Romero, A ^a   Martos, A I ^a   Canton E ^b   Peman J ^b   Martos, P García ^c   Martin Mazuelos E ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Antifungals; Aspergillus; Triazoles

Indexed keywords

4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; CONTROLLED STUDY; DILUTION; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; FUSARIUM; HYPHOMYCETES; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUCOR; MUCORALES; NONHUMAN; RHIZOPUS; SCEDOSPORIUM PROLIFICANS; ZYGOMYCETES;

ANTIFUNGAL AGENTS; FUNGI; MICROBIAL SENSITIVITY TESTS; NITRILES; TRIAZOLES;

EID: 42149119502     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn076     Document Type: Article

References (17)

1. Groll AH, Kurz M, Scheneider W et al. Five-year-survey of invasive aspergillosis in a paediatric cancer centre: Epidemiology, management and long-term survival. Mycoses 1999; 42: 431-42.
2. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-66.
3. Manavathu EK, Cutright JL, Loebenberg D et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH56592). J Antimicrob Chemother 2000; 46: 229-34.
4. Diekema DJ, Messer SA, Hollins RJ et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-6.
5. Warn P, Sharp A, Denning D et al. In vitro activity of a new triazole BAL8557, the water-soluble prodrug of BAL4815, in a temporarily neutropenic murine model of disseminated Aspergillus flavus. In: Abstracts of the First Advances Against Aspergillosis Conference, San Francisco, CA, USA, 2004. Abstract 86, p. 105. Med Mycol 2005; 43 Suppl 1.
6. Schmitt-Hoffman A, Ross B, Heep M et al. Pharmacokinetics of BAL4815, a new azole antifungal, after administration of single ascending intravenous doses of its pro-drug BAL8557. In: Abstracts of the Fourteenth European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, 2004. Poster P1033. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
7. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard M38-A. NCCLS, Wayne, PA, USA, 2002.
8. Espinel-Ingroff A, Fothergill A, Peter J et al. Testing conditions for determination of minimal fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS Collaborative Study. J Clin Microbiol 2002; 40: 3204-8.
9. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the weter-soluble, prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57 135-8.
10. Gonzalez G, Heep M. In vitro activity of BAL4815, a new water-soluble broad spectrum triazole, against opportunistic filamentous and dimorphic fungi. In: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology, Paris, France, 2006 Abstract P-0081.
11. Warn P, Sharp A, Denning D. In vitro activity of BAL 4815 against zygomycetes. In: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology, Paris, France, 2006 Abstract P-0158.
12. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-8.
13. López-Oviedo E, Aller Al, Martín C et al. Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: Comparison with CLSI broth microdilution method. Antimicrob Agents Chemother 2006; 50: 1108-11.
14. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinicandins MK-0091 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-6.
15. Pfaller MA, Messer SA, Hollis RJ et al. Antifungal activities of posaconazolo, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-7.
16. Diekema DJ, Messer SA, Hollis RJ et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 went clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-6.
17. Dannaoui E, Meletiadis J, Mouton JW et al. In vitro susceptibilities of zygomycetes to conventional and now antifungals. J Antimicrob Chemother 2003; 51: 45-52.